
FDA Grants De Novo Authorization to 5-Year Breast Cancer Risk Prediction Device
Clarity Breast, a novel, image-based prognostic platform designed to predict 5-year breast cancer risk from a routine screening mammogram, has received FDA de novo authorization, advancing precision medicine to transform breast cancer care.1 “For more than …